Alopecia Areata in an Adolescent With Inflammatory Bowel Disease

Sankararaman, Senthilkumar; Bobonich, Margaret; Aktay, Atiye

doi:10.1177/0009922816678185

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although intralesional corticosteroid (triamcinolone) therapy is effective, these studies are rare in children due to the pain associated with the injections. 48 Based on data on adult patients, the most common side effects are pain, skin atrophy, and dyspigmentation. Other adverse effects are rare, although anaphylaxis and cataracts and increased intraocular pressure, if used close to the eyes, have been reported.…”

Section: Resultsmentioning

confidence: 99%

Treatment of pediatric alopecia areata: A systematic review

Barton

Toussi

Awasthi

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is lacking.Objective: To evaluate the evidence of current treatment modalities for pediatric AA. Methods:We conducted a systematic review on the PubMed database in October 2019 for all published articles involving patients \18 years old. Articles discussing AA treatment in pediatric patients were included, as were articles discussing both pediatric and adult patients, if data on individual pediatric patients were available.Results: Inclusion criteria were met by 122 total reports discussing 1032 patients. Reports consisted of 2 randomized controlled trials, 4 prospective comparative cohorts, 83 case series, 2 case-control studies, and 31 case reports. Included articles assessed the use of aloe, apremilast, anthralin, anti-interferon gamma antibodies, botulinum toxin, corticosteroids, contact immunotherapies, cryotherapy, hydroxychloroquine, hypnotherapy, imiquimod, Janus kinase inhibitors, laser and light therapy, methotrexate, minoxidil, phototherapy, psychotherapy, prostaglandin analogs, sulfasalazine, topical calcineurin inhibitors, topical nitrogen mustard, and ustekinumab.Limitations: English-only articles with full texts were used. Manuscripts with adult and pediatric data were only incorporated if individual-level data for pediatric patients were provided. No meta-analysis was performed. Conclusion:Topical corticosteroids are the preferred first-line treatment for pediatric AA, as they hold the highest level of evidence, followed by contact immunotherapy. More clinical trials and comparative studies are needed to further guide management of pediatric AA and to promote the potential use of pre-existing, low-cost, and novel therapies, including Janus kinase inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

Treatment of pediatric alopecia areata: A systematic review

Barton

Toussi

Awasthi

et al. 2022

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

show abstract

“…Seventeen individual case studies described the association between hair loss and IBD ( n = 17, 35.2% female), with a mean patient age of 27.7 years [9, 21-24, 27, 34, 38, 43, 46, 48, 49, 51, 54, 56, 59, 61]. Of these 17 patients, 8 (47%) were diagnosed with AA (Table 3).…”

Section: Meta-analysismentioning

confidence: 99%

“…Seven (41.17%) patients required systemic therapy for IBD, which resulted in some degree of hair growth; 2 (11.1%) patients failed to regrow hair despite stable IBD disease [24, 34]. However, there were 2 (11.1%) patients who experienced resolution of alopecia with localized AA treatment (topical clobetasol, minoxidil, and serial triamcinolone injections) [21, 48].…”

Section: Meta-analysismentioning

confidence: 99%

The Association between Alopecia and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Importance: The link between autoimmune gut disorders and different types of hair loss conditions has been recently investigated with an increased interest. With acknowledgement of the connection between immune dysregulation and the gut microbiome, this pathway is now becoming recognized as playing an important role in hair growth. The inflammatory cascade that results from the disruption of gut integrity such as seen in inflammatory bowel diseases (IBD) has been associated with certain types of alopecia. Objective: The aim of this work was to evaluate the association between alopecia and IBD. Evidence Review: A primary literature search was conducted using the PubMed, Embase, and Web of Science databases to identify articles on co-occurring alopecia and IBD from 1967 to 2020. A total of 79 studies were included in the review. A one-way proportional meta-analysis was performed on 19 of the studies to generate the pooled prevalence of alopecia and IBD. Finding: The pooled prevalence of non-scarring alopecia among IBD patients was 1.12% (k = 7, I2 = 98.6%, 95% CI 3.1–39.9); the prevalence of IBD among scarring and non-scarring alopecia was 1.99% (k = 12; I2 = 99%, 95% CI 6.2–34). The prevalence of non-scarring alopecia areata (AA) among IBD was compared to the prevalence of AA in the general population (0.63 vs. 0.1%; p < 0.0001). Similarly, the prevalence of IBD among the scarring and non-scarring alopecia groups was compared to the prevalence of IBD in the general population (1.99 vs. 0.396%; p = 0.0004). Conclusion: IBD and alopecia, particularly AA, appear to be strongly associated. Dermatology patients with alopecia may benefit from screening for IBD.

show abstract

Methotrexate

2017

Reactions Weekly

View full text Add to dashboard Cite

Alopecia Areata in an Adolescent With Inflammatory Bowel Disease

Cited by 3 publications

References 20 publications

Treatment of pediatric alopecia areata: A systematic review

Treatment of pediatric alopecia areata: A systematic review

The Association between Alopecia and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Methotrexate

Contact Info

Product

Resources

About